EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Influence of interleukin-6 on the pharmacokinetics and pharmacodynamics of osimertinib in patients with non-small cell lung cancer

Hayato Yokota, Kazuhiro Sato, Sho Sakamoto, Yuji Okuda, Masahide Takeda, Yumiko Akamine, Katsutoshi Nakayama, Masatomo Miura

Cancer Chemotherapy and Pharmacology · 2025-12 · 95 (1)

DOI: 10.1007/s00280-025-04772-x ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Chemotherapy and Pharmacology, online erschienen am 29.03.2025. Verfasst von Hayato Yokota und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, Akita University Hospital, Akita, Japan. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Interleukin-6, Aniline Compounds, Acrylamides. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Akita University.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

The inflammatory cytokine interleukin (IL)-6 reduces the activity of drug metabolic enzymes and promotes tumor progression. We investigated the effect of IL-6 on the pharmacokinetics of osimertinib and the association between an IL-6 polymorphism and clinical outcomes in 30 patients with non-small cell lung cancer (NSCLC).

Methods

Osimertinib and IL-6 plasma concentrations were measured on day 15 after therapy initiation. The genotype of IL-6 1800796G > C was identified using polymerase chain reaction–restriction fragment length polymorphism. Risk factors affecting overall survival (OS) were assessed by Cox proportional hazard regression analysis.

Results

The IL-6 concentration was significantly correlated with the osimertinib trough plasma concentration ( r = 0.423, P = 0.020) and area under the plasma concentration–time curve ( r = 0.420, P = 0.021). The IL-6 concentration was significantly higher in patients with the IL-6 rs1800796G allele versus C/C genotype ( P = 0.024). OS was significantly shorter in patients with the IL-6 rs1800796G allele versus C/C genotype (median: 15.1 vs. 48.9 months, P = 0.005). Univariate and multivariate analyses indicated that the IL-6 rs1800796G allele is an independent risk factor for OS (crude hazard ratio = 7.07; P = 0.014; adjusted hazard ratio = 6.38; P = 0.021).

Conclusion

A higher IL-6 concentration was associated with reduced metabolic activity of osimertinib, leading to increased osimertinib exposure. As the IL-6 concentration was higher in NSCLC patients with the IL-6 rs1800796G allele, it might be an independent prognostic factor for patients treated with osimertinib.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Non-Small-Cell LungInterleukin-6Aniline CompoundsAcrylamidesLung NeoplasmsAntineoplastic AgentsPiperazinesHumansFemaleMaleMiddle AgedAgedGenotypeAdultPolymorphism, Single NucleotideIndolesPyrimidines

Stichwörter der Autor:innen

Area under the plasma concentration–time curveInterleukin-6OsimertinibOverall survivalPolymorphismTrough concentration

Substanzen

osimertinibInterleukin-6Aniline CompoundsAcrylamidesIL6 protein, humanAntineoplastic AgentsPiperazinesIndolesPyrimidines

Autor:innen und Institutionen

  • Department of Pharmacy, Akita University Hospital, Akita, Japan.
  • Department of Internal Medicine Division of Respiratory Medicine, Akita University School of Medicine, Akita, Japan.
  • Department of Pharmacy, Akita University Hospital, Akita, Japan. m-miura@hos.akita-u.ac.jp.
  • Department of Pharmacokinetics, Akita University Graduate School of Medicine, 1-1-1 Hondo, Akita, 010-8543, Japan. m-miura@hos.akita-u.ac.jp.

Förderung

  • Akita University

Zitieren

APA

Yokota, H., Sato, K., Sakamoto, S., Okuda, Y., Takeda, M., Akamine, Y., Nakayama, K., & Miura, M. (2025). Influence of interleukin-6 on the pharmacokinetics and pharmacodynamics of osimertinib in patients with non-small cell lung cancer. Cancer Chemotherapy and Pharmacology, 95(1). https://doi.org/10.1007/s00280-025-04772-x

Vancouver

Yokota H, Sato K, Sakamoto S, Okuda Y, Takeda M, Akamine Y, et al. Influence of interleukin-6 on the pharmacokinetics and pharmacodynamics of osimertinib in patients with non-small cell lung cancer. Cancer Chemotherapy and Pharmacology. 2025;95(1). doi:10.1007/s00280-025-04772-x

BibTeX
@article{Yokota2025,
  author = {Yokota, Hayato and Sato, Kazuhiro and Sakamoto, Sho and Okuda, Yuji and Takeda, Masahide and Akamine, Yumiko and Nakayama, Katsutoshi and Miura, Masatomo},
  title = {Influence of interleukin-6 on the pharmacokinetics and pharmacodynamics of osimertinib in patients with non-small cell lung cancer},
  journal = {Cancer Chemotherapy and Pharmacology},
  year = {2025},
  volume = {95},
  number = {1},
  doi = {10.1007/s00280-025-04772-x}
}
Kostenlos starten →